Gastrointestinal Cancer | Specialty

Dr. Iveson on the IDEA Collaboration in CRC

August 14th 2019

Tim Iveson, MD, FACP, discusses the International Duration Evaluation of Adjuvant Chemotherapy Collaboration, which examines the effects of adjuvant oxaliplatin-based therapy given for 3 months versus 6 months in patients with high-risk stage II colorectal cancer.

Ripretinib Improves PFS in Advanced GIST

August 13th 2019

Ripretinib (DCC-2618) improved progression-free survival compared with placebo in patients with fourth-line and fourth-line plus advanced gastrointestinal stromal tumors, according to topline findings of the phase III INVICTUS study (NCT03353753).

Dr. Sahai on Sequencing Strategies in Metastatic Pancreatic Cancer

August 12th 2019

Vaibhav Sahai, MBBS, assistant professor of medicine at the University of Michigan, discusses sequencing strategies in metastatic pancreatic cancer.

Dr. El-Khoueiry Discusses Research on Biomarkers in HCC

August 10th 2019

Anthony B. El-Khoueiry, MD, associate professor of clinical medicine, Keck School of Medicine, USC Norris Comprehensive Cancer Center, discusses research on biomarkers in hepatocellular carcinoma (HCC).

PARP Inhibition Arrives in Pancreatic Cancer

August 9th 2019

Michael J. Hall, MD, Fox Chase Cancer Center, discusses the emergence of PARP inhibition in the armamentarium for patients with pancreatic cancer.

Dr. Hochster on the Safety Analysis of TAS-102 in CRC and Gastric/GEJ Cancer

August 8th 2019

Howard Hochster, MD, FACP, associate director for clinical research and director, Gastrointestinal Oncology, Rutgers Cancer Institute of New Jersey, director of oncology research, RWJBarnabas Health, discusses the safety analysis of TAS-102 in metastatic colorectal cancer and metastatic gastric/gastroesophageal junction cancer.

FDA Grants Priority Review to Avapritinib for GIST

August 8th 2019

The FDA has granted a priority review designation to a new drug application for avapritinib for the treatment of adult patients with PDGFRA exon 18–mutant gastrointestinal stromal tumors, regardless of prior therapy, as well as for patients with GIST in the fourth-line setting.

Dr. Lieu Discusses the Rationale for Combined MEK/VEGF/PD-1 Inhibition in CRC

August 8th 2019

Christopher Lieu, MD, director, GI Medical Oncology Program and deputy associated director for clinical research, at the University of Colorado Cancer Center, discusses the rationale for combined MEK, VEGF, and PD-1 inhibition in microsatellite stable (MSS) colorectal cancer (CRC).

Newfound Understandings of Neuroendocrine Treatment in Kentucky

August 7th 2019

We traveled to Lexington, Kentucky, for a State of the Science Summit™ on Neuroendocrine Tumors, which featured insights from the faculty from University of Kentucky Markey Cancer Center.

Dr. Messersmith on the Need for Biomarkers to Distinguish Between VEGF Inhibitors in CRC

August 7th 2019

Wells A. Messersmith, MD, co-leader of the Developmental Therapeutics Program, and director, GI Cancer Program, and professor of medicine, at the University of Colorado School of Medicine, discusses the need for biomarkers to distinguish between VEGF inhibitors in colorectal cancer (CRC).

Dr. Llovet on Efficacy of Namodenoson in Child-Pugh B HCC

August 6th 2019

Josep M. Llovet, MD, discusses a phase II, double-blind, placebo-controlled trial examining the efficacy and safety of namodenoson, an A3 adenosine receptor agonist, as a second-line treatment for patients with Child-Pugh B advanced hepatocellular carcinoma.

NY-ESO-1 Gains Momentum as a Therapeutic Target

August 2nd 2019

As the immunotherapy research field grows, NY-ESO-1 is emerging as a high-priority target for cancer vaccine development and adoptive T-cell therapies.

Investigators Test Immunotherapy Combo in HCC

August 2nd 2019

Investigators hope to expand frontline treatment options for patients with hepatocellular carcinoma via the phase III IMbrave150 study, which is exploring the synergistic potential of immunotherapy and the immunomodulatory potential of a VEGF inhibitor in locally advanced, metastatic or unresectable HCC.

Dr. Kasi on the Use of Liquid Biopsies in CRC

August 2nd 2019

Pashtoon M. Kasi, MBBS, MD, MS, hematologist, internist, oncologist, Mayo Clinic, discusses the comparison of circulating tumor DNA tests, tissue, and liquid biopsies, in a study of patients with colorectal cancer.

Can We Preempt Emergency Department Diagnoses of Stomach Cancer?

August 1st 2019

It is crucial to develop screening programs for stomach cancer in the United States in order to make diagnoses at earlier stages of disease, provide better care, and improve outcomes.

Novel Therapies for BRAF+ Colorectal Cancer

July 31st 2019

Treating BRAF+ Colorectal Cancer

July 31st 2019

Targeting BRAF and MEK in Colorectal Cancer

July 31st 2019

BRAF Mutations in Colorectal Cancer

July 31st 2019

Emerging Treatment Strategies for Advanced BRAF+ Melanoma

July 31st 2019